Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma

• Published in: The American journal of medicine Vol. 112; no. 6; pp. 446 - 452
• Main Authors: Little, Stuart A, MacLeod, Kirsten J, Chalmers, George W, Love, Janet G, McSharry, Charles, Thomson, Neil C
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 15.04.2002; Elsevier; Elsevier Sequoia S.A
• Subjects: Administration, Topical; Adult; Albuterol - administration & dosage; Androstadienes - administration & dosage; Anti-Inflammatory Agents - administration & dosage; Asthma; Asthma - drug therapy; Asthma - pathology; Asthma - physiopathology; Biological and medical sciences; Bronchodilator Agents - administration & dosage; Chronic asthma; Chronic Disease; Chronic obstructive pulmonary disease, asthma; Clinical Trials as Topic; Female; Fluticasone; Forced Expiratory Volume - drug effects; Glucocorticoids; Humans; Induced sputum neutrophils; Irreversible airflow obstruction; Leukocyte Count; Linear Models; Male; Medical research; Medical sciences; Middle Aged; Neutrophils - drug effects; Pneumology; Prednisolone - administration & dosage; Respiratory system; Spirometry; Sputum - drug effects; Time Factors; Irreversible airflow obstruction; Induced sputum neutrophils; Chronic asthma; Human; Respiratory disease; Cytology; Maximal expiratory volume per second; Statistical study; Obstruction; Asthma; Respiratory tract; Chronic; Sputum; Risk factor; Complication; Obstructive pulmonary disease; Neutrophil; Exposure time
• ISSN: 0002-9343; 1555-7162
• DOI: 10.1016/S0002-9343(02)01047-1

Some patients with chronic asthma develop irreversible airflow obstruction. Our aim was to assess whether reported duration of asthma and induced sputum cell counts were associated with pulmonary function in patients with asthma who did not smoke. Maximal forced expiratory volume in the first second (FEV1) was determined following a steroid trial (oral prednisolone, 30 mg/d [n = 92 patients]; or inhaled fluticasone, 2000 μg/d [n = 5]; for 2 weeks) and 2.5 mg of nebulized albuterol. Asthma history was recorded with duration from first diagnosis. All subjects were nonsmokers, or were to have stopped smoking ≥5 years previously and smoked ≤5 pack-years (n = 12). Induced sputum was obtained from 59 subjects for analysis of airway cell counts. Maximal FEV1 was inversely associated with asthma duration (r = −0.47, P <0.0001), age (r = −0.40, P <0.0001), and the proportion of sputum neutrophils (rs = −0.50, P = 0.00004). After adjusting for age, both duration of disease and sputum neutrophils were independently associated with maximal FEV1. Neutrophil activation, as measured by sputum myeloperoxidase levels, was positively associated with the proportion of sputum neutrophils (rs = 0.45, P = 0.0004) and inversely associated with maximal FEV1 (rs = −0.59, P <0.0001). Long disease duration may be a predisposing factor for the development of irreversible airflow obstruction in patients with chronic asthma. The negative associations of sputum neutrophil count and activation with maximal FEV1 suggest that neutrophils may be involved in the pathophysiology of irreversible airflow obstruction in asthma.